Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 8/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | GSK3A | P49840 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1491105 | 0.89 | ALDH1A1 (0.51) | ALDH1A1PKMKDM4ESIGMAR1ADORA2A | |
| SCHEMBL1491133 | 0.80 | TAAR1 (0.45) | ALDH1A1PKMKDM4EMAOB | |
| SCHEMBL1491131 | 0.80 | FLT1 (0.42) | ALDH1A1PKMKDM4ESIGMAR1ADORA2A | |
| SCHEMBL568868 | 0.78 | KDM4E (0.72) | ALDH1A1PKMKDM4EPOLB | |
| SCHEMBL27546858 | 0.75 | GSK3A (0.49) | ALDH1A1PKMSIGMAR1GSK3AGSK3B | |
| SCHEMBL10725199 | 0.74 | KDM4E (0.47) | ALDH1A1PKMKDM4EPOLB | |
| SCHEMBL27986966 | 0.74 | KDM4E (0.47) | ALDH1A1PKMKDM4EPOLB | |
| SCHEMBL9442047 | 0.74 | KDM4E (0.47) | ALDH1A1PKMKDM4EADORA2AADORA1 | |
| SCHEMBL27663557 | 0.73 | CES1 (0.47) | ALDH1A1 | |
| SCHEMBL438493 | 0.73 | KDM4E (0.46) | ALDH1A1PKMKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110086889-A1 | TETRAZOLE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-04-14 | — | — | US | disclosed |
| EP-2288603-A1 | TETRAZOLE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2011-03-02 | — | — | EP | disclosed |
| WO-2009150614-A1 | TETRAZOLE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110086889-A1 | TETRAZOLE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY1R | ALDH1A1 3233/4885PKM 2177/4885KDM4E 2955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.